Pre-earnings options volume in I MAB (ADS) is normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 11.8%, or 61c, after results are released. Median move over the past eight quarters is 2.3%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-Mab Completes Enrollment in Phase 1b Study for Givastomig in Gastric Cancer
- I-Mab completes enrollment in Phase 1b dose expansion study for givastomig
- 3 Penny Stocks to Watch Now, 8/5/25
- I-Mab Announces $65 Million ADS Offering to Advance Cancer Treatment Pipeline
- Everest Medicines announces strategic equity investment in I-Mab